{"id":25881,"date":"2023-12-11T17:39:16","date_gmt":"2023-12-11T12:09:16","guid":{"rendered":"https:\/\/www.delveinsight.com\/blog\/?p=25881"},"modified":"2024-01-05T10:04:46","modified_gmt":"2024-01-05T04:34:46","slug":"jaypirca-for-chronic-lymphocytic-leukemia","status":"publish","type":"post","link":"https:\/\/www.delveinsight.com\/blog\/jaypirca-for-chronic-lymphocytic-leukemia","title":{"rendered":"Eli\u2019s Jaypirca: A Beacon of Success in the BTK Inhibitor Market"},"content":{"rendered":"\n

As the battle intensifies among AbbVie, Johnson & Johnson, AstraZeneca, and BeiGene<\/strong> in the BTK inhibitor market<\/a>, Eli Lilly<\/strong> stands out by forging a new direction in the landscape of blood cancer drugs. Just at the beginning of this month, the FDA granted accelerated approval to Lilly\u2019s Jaypirca<\/strong>. This approval is significant for patients with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) who have undergone at least two prior lines of therapy. What sets Jaypirca apart is that, as a BTK inhibitor, it is now authorized for use after treatment with both a BTK inhibitor and a BCL-2 inhibitor.<\/p>\n\n\n\n

Nearly a year since Jaypirca secured its initial approval in January 2023<\/strong> for treating adults with relapsed or refractory mantle cell lymphoma, this recent FDA approval marks another significant milestone. Jaypirca remains the sole FDA-approved reversible BTK inhibitor available in the market.<\/p>\n\n\n\n

Chronic lymphocytic leukemia (CLL) is a type of blood cancer that primarily affects the lymphocytes, a type of white blood cell crucial for the immune system. CLL is the most common form of leukemia in adults, particularly in Western countries. As per DelveInsight analysis, chronic lymphocytic leukemia prevalence<\/a> tends to increase with age, with the majority of cases diagnosed in individuals over 60<\/strong>.<\/p>\n\n\n\n

\n

\u201cFollowing progression on covalent BTK inhibitor and BCL-2 inhibitor therapies in patients with CLL or SLL, treatment options become limited, and the prognosis can be unfavorable. The approval of Jaypirca represents a significant advancement and a much-needed addition to the therapeutic arsenal for these patients,\u201d commented <\/em>Dr. William G. Wierda, Professor, Medical Director, and CLL Section Head for the Department of Leukemia at The University of Texas MD Anderson Cancer Center.<\/em><\/strong> \u201cJaypirca introduces a novel treatment approach, targeting BTK in a distinctive manner, and it has demonstrated clinical efficacy for a substantial number of patients with CLL or SLL in the BRUIN Phase I\/II trial, particularly those whose disease progressed after undergoing covalent BTK inhibitor and BCL-2 inhibitor treatments.\u201d<\/em><\/p>\n<\/blockquote>\n\n\n\n

Eli Lilly\u2019s Jaypirca acts as a small molecule inhibitor specifically designed to target the BTK enzyme. This enzyme is normally instrumental in the development, proliferation, and function of B lymphocytes, making BTK a recognized and validated target in various leukemias and lymphomas.<\/p>\n\n\n\n

While drugs like Imbruvica (ibrutinib)<\/strong> by J&J<\/strong> and Calquence (acalabrutinib)<\/strong> from AstraZeneca <\/strong>rely on covalent interactions to disrupt BTK activity, Jaypirca distinguishes itself by establishing non-covalent connections. This unique mechanism not only prevents the development of resistance, often linked to covalent bonds but also enables Jaypirca to exert its effects on both wildtype and mutated BTK. Unlike traditional BTK blockers, Jaypirca\u2019s action is not contingent on the presence of specific amino acid residues at the enzyme\u2019s active site.<\/p>\n\n\n\n

\n

\u201cThe recent FDA clearance, marking Jaypirca\u2019s second approval in 2023, highlights the significant clinical advantages of persistently tapping into the BTK pathway in CLL or SLL patients, as demonstrated in the BRUIN trial,\u201d commented <\/em>Jacob Van Naarden, CEO of Loxo@Lilly<\/em><\/strong>. \u201cThese initial two endorsements for Jaypirca mark the commencement of the potential impact we envision for patients, and we eagerly anticipate the outcomes of the comprehensive Phase III development program encompassing CLL, SLL, and MCL.\u201d<\/em><\/p>\n<\/blockquote>\n\n\n\n

\n

\u201cThe advancements in treating CLL have been significant with the advent of covalent BTK inhibitors and BCL-2 inhibitors. Despite these improvements, a majority of patients may experience relapse over time,” stated <\/em>Dr. Brian Koffman, Chief Medical Officer, and Executive Vice President at the CLL Society.<\/em><\/strong> \u201cThe approval of Pirtobrutinib offers a crucial alternative for patients, opening up new avenues in their treatment course.\u201d<\/em><\/p>\n<\/blockquote>\n\n\n\n

Despite the rapid FDA approval, the path taken isn\u2019t without drawbacks. Prior disclosures reveal Lilly\u2019s pursuit of accelerated approval in the third line, leveraging tumor shrinkage data from the single-arm BRUIN phase I\/II trial. Notably, this trial encompassed patients who had previously received a BTK inhibitor<\/a> but not a BCL-2 inhibitor like AbbVie and Roche\u2019s Venclexta<\/strong>.<\/p>\n\n\n\n

\"Jaypirca<\/figure>\n\n\n\n

Jaypirca\u2019s recent approval stems from data derived from a subgroup of participants in the Phase I\/II BRUIN study<\/strong>. Among 108 CLL or SLL patients subjected to a once-daily 200-mg Jaypirca dose, a noteworthy 72% objective response rate was observed, with a median time to response standing at 3.7 months. The treatment response, evaluated by an independent review committee, exhibited a median duration of 12.2 months.<\/p>\n\n\n\n

Regarding safety, 56% of Jaypirca-treated patients encountered serious side effects, with the predominant issues being pneumonia, COVID-19, sepsis, and febrile neutropenia. Adverse events prompted treatment interruptions in 42% of the treated cohort, along with dose reductions in 3.6%. Notably, 9% of patients permanently ceased Jaypirca treatment due to associated toxicities.<\/p>\n\n\n\n

In adherence to the FDA\u2019s accelerated pathway requirements and to maintain Jaypirca\u2019s market presence, Lilly is conducting Phase III BRUIN CLL-321<\/strong>. This open-label, randomized study serves as Jaypirca\u2019s confirmatory trial, comparing its efficacy against idelalisib or bendamustine combined with rituximab in CLL or SLL. Lilly has communicated topline data from BRUIN CLL-321<\/strong> to the FDA and commits to sharing it with the wider medical community during an upcoming congress.<\/p>\n\n\n\n

Another ongoing trial, BRUIN CLL-322<\/strong>, is investigating the combination of Jaypirca with Venclexta and rituximab in patients with previously treated CLL\/SLL. These individuals may or may not have received prior treatment with a BTK inhibitor. In contrast to the current Jaypirca regimen, where the chronic lymphocytic leukemia drug<\/a> is administered until disease progression or unacceptable toxicity, the BRUIN CLL-322 trial<\/strong> discontinues Jaypirca after a specified duration. Furthermore, Lilly\u2019s BRUIN CLL-313 trial<\/strong> is examining Jaypirca as compared to the bendamustine-rituximab combination in CLL\/SLL patients who have not received prior treatment.<\/p>\n\n\n\n

The three covalent treatment options are currently competing at the forefront of the chronic lymphocytic leukemia treatment market<\/a>, and Imbruvica is experiencing a decrease in market share. In the third quarter of 2023, BeiGene <\/strong>witnessed a remarkable 150%<\/strong> year-over-year increase in Brukinsa sales, reaching $270 million in the US AstraZeneca\u2019s Calquence also saw a 2%<\/strong> sales growth, reaching $468 million<\/strong> in the U.S. during Q3. Meanwhile, AbbVie reported a 20%<\/strong> decline in Imbruvica\u2019s US revenue, which amounted to $678 million<\/strong>.<\/p>\n\n\n\n

Jaypirca received its initial FDA approval in January as a third-line treatment for mantle cell lymphoma<\/a> after BTK inhibitor therapy. Despite its limited indication, Jaypirca generated $22.7 million<\/strong> in sales in Q3. The confirmatory trial for its accelerated approval, BRUIN MCL-321<\/strong>, is currently comparing Jaypirca with the investigator\u2019s choices such as Imbruvica, Calquence, or Brukinsa<\/strong> in MCL patients who have undergone at least one prior line of therapy.<\/p>\n\n\n\n

\"Chronic<\/a><\/figure>\n","protected":false},"excerpt":{"rendered":"

As the battle intensifies among AbbVie, Johnson & Johnson, AstraZeneca, and BeiGene in the BTK inhibitor market, Eli Lilly stands out by forging a new direction in the landscape of blood cancer drugs. Just at the beginning of this month, the FDA granted accelerated approval to Lilly\u2019s Jaypirca. This approval is significant for patients with […]<\/p>\n","protected":false},"author":14,"featured_media":25882,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"_editorskit_title_hidden":false,"_editorskit_reading_time":0,"_editorskit_is_block_options_detached":false,"_editorskit_block_options_position":"{}","advgb_blocks_editor_width":"","advgb_blocks_columns_visual_guide":"","footnotes":""},"categories":[17],"tags":[21528,132,18438,18442,21530,21529,228,17737,21527,18443,1597],"industry":[17225],"therapeutic_areas":[17233],"class_list":["post-25881","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-articles","tag-btk-inhibitor-market","tag-btk-inhibitors","tag-calquence","tag-chronic-lymphocytic-leukemia","tag-chronic-lymphocytic-leukemia-treatment","tag-chronic-lymphocytic-leukemia-treatment-market","tag-eli-lilly","tag-imbruvica","tag-jaypirca","tag-small-lymphocytic-lymphoma","tag-venclexta","industry-pharmaceutical","therapeutic_areas-hematological-disorders"],"acf":[],"yoast_head":"\nEli\u2019s Jaypirca\u2019s Triumph in the BTK Inhibitor Landscape<\/title>\n<meta name=\"description\" content=\"FDA granted accelerated approval to Lilly\u2019s Jaypirca for chronic lymphocytic leukemia or small lymphocytic lymphoma patients.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.delveinsight.com\/blog\/jaypirca-for-chronic-lymphocytic-leukemia\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Eli\u2019s Jaypirca\u2019s Triumph in the BTK Inhibitor Landscape\" \/>\n<meta property=\"og:description\" content=\"FDA granted accelerated approval to Lilly\u2019s Jaypirca for chronic lymphocytic leukemia or small lymphocytic lymphoma patients.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.delveinsight.com\/blog\/jaypirca-for-chronic-lymphocytic-leukemia\" \/>\n<meta property=\"og:site_name\" content=\"DelveInsight Business Research\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/DelveInsight-1423323754607782\/\" \/>\n<meta property=\"article:published_time\" content=\"2023-12-11T12:09:16+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2024-01-05T04:34:46+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2023\/12\/11160058\/jaypirca-for-chronic-lymphocytic-leukemia.png\" \/>\n\t<meta property=\"og:image:width\" content=\"772\" \/>\n\t<meta property=\"og:image:height\" content=\"482\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"Sandeep Joshi\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:creator\" content=\"@DelveInsight\" \/>\n<meta name=\"twitter:site\" content=\"@DelveInsight\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Sandeep Joshi\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"4 minutes\" \/>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Eli\u2019s Jaypirca\u2019s Triumph in the BTK Inhibitor Landscape","description":"FDA granted accelerated approval to Lilly\u2019s Jaypirca for chronic lymphocytic leukemia or small lymphocytic lymphoma patients.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.delveinsight.com\/blog\/jaypirca-for-chronic-lymphocytic-leukemia","og_locale":"en_US","og_type":"article","og_title":"Eli\u2019s Jaypirca\u2019s Triumph in the BTK Inhibitor Landscape","og_description":"FDA granted accelerated approval to Lilly\u2019s Jaypirca for chronic lymphocytic leukemia or small lymphocytic lymphoma patients.","og_url":"https:\/\/www.delveinsight.com\/blog\/jaypirca-for-chronic-lymphocytic-leukemia","og_site_name":"DelveInsight Business Research","article_publisher":"https:\/\/www.facebook.com\/DelveInsight-1423323754607782\/","article_published_time":"2023-12-11T12:09:16+00:00","article_modified_time":"2024-01-05T04:34:46+00:00","og_image":[{"width":772,"height":482,"url":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2023\/12\/11160058\/jaypirca-for-chronic-lymphocytic-leukemia.png","type":"image\/png"}],"author":"Sandeep Joshi","twitter_card":"summary_large_image","twitter_creator":"@DelveInsight","twitter_site":"@DelveInsight","twitter_misc":{"Written by":"Sandeep Joshi","Est. reading time":"4 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/www.delveinsight.com\/blog\/jaypirca-for-chronic-lymphocytic-leukemia","url":"https:\/\/www.delveinsight.com\/blog\/jaypirca-for-chronic-lymphocytic-leukemia","name":"Eli\u2019s Jaypirca\u2019s Triumph in the BTK Inhibitor Landscape","isPartOf":{"@id":"https:\/\/www.delveinsight.com\/blog\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.delveinsight.com\/blog\/jaypirca-for-chronic-lymphocytic-leukemia#primaryimage"},"image":{"@id":"https:\/\/www.delveinsight.com\/blog\/jaypirca-for-chronic-lymphocytic-leukemia#primaryimage"},"thumbnailUrl":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2023\/12\/11160058\/jaypirca-for-chronic-lymphocytic-leukemia.png","datePublished":"2023-12-11T12:09:16+00:00","dateModified":"2024-01-05T04:34:46+00:00","author":{"@id":"https:\/\/www.delveinsight.com\/blog\/#\/schema\/person\/f1eefd8dd4afdb0617d6166f8b301e0a"},"description":"FDA granted accelerated approval to Lilly\u2019s Jaypirca for chronic lymphocytic leukemia or small lymphocytic lymphoma patients.","inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.delveinsight.com\/blog\/jaypirca-for-chronic-lymphocytic-leukemia"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.delveinsight.com\/blog\/jaypirca-for-chronic-lymphocytic-leukemia#primaryimage","url":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2023\/12\/11160058\/jaypirca-for-chronic-lymphocytic-leukemia.png","contentUrl":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2023\/12\/11160058\/jaypirca-for-chronic-lymphocytic-leukemia.png","width":772,"height":482,"caption":"jaypirca-for-chronic-lymphocytic-leukemia"},{"@type":"WebSite","@id":"https:\/\/www.delveinsight.com\/blog\/#website","url":"https:\/\/www.delveinsight.com\/blog\/","name":"DelveInsight Business Research","description":"Blog","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.delveinsight.com\/blog\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.delveinsight.com\/blog\/#\/schema\/person\/f1eefd8dd4afdb0617d6166f8b301e0a","name":"Sandeep Joshi","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.delveinsight.com\/blog\/#\/schema\/person\/image\/","url":"https:\/\/secure.gravatar.com\/avatar\/7676451175fe155887a18ffb50e674b270d87436a3fc34ca206f86921cddf4cd?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/7676451175fe155887a18ffb50e674b270d87436a3fc34ca206f86921cddf4cd?s=96&d=mm&r=g","caption":"Sandeep Joshi"},"sameAs":["http:\/\/Delveinsight.com"]}]}},"author_meta":{"display_name":"Sandeep Joshi","author_link":"https:\/\/www.delveinsight.com\/blog\/author\/sjoshidelveinsight-com"},"featured_img":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2023\/12\/11160058\/jaypirca-for-chronic-lymphocytic-leukemia-300x187.png","coauthors":[],"tax_additional":{"categories":{"linked":["<a href=\"https:\/\/www.delveinsight.com\/blog\/articles\/\" class=\"advgb-post-tax-term\">Articles<\/a>"],"unlinked":["<span class=\"advgb-post-tax-term\">Articles<\/span>"]},"tags":{"linked":["<a href=\"https:\/\/www.delveinsight.com\/blog\/articles\/\" class=\"advgb-post-tax-term\">BTK Inhibitor Market<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/articles\/\" class=\"advgb-post-tax-term\">BTK Inhibitors<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/articles\/\" class=\"advgb-post-tax-term\">Calquence<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/articles\/\" class=\"advgb-post-tax-term\">Chronic Lymphocytic Leukemia<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/articles\/\" class=\"advgb-post-tax-term\">chronic lymphocytic leukemia treatment<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/articles\/\" class=\"advgb-post-tax-term\">chronic lymphocytic leukemia treatment market<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/articles\/\" class=\"advgb-post-tax-term\">Eli Lilly<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/articles\/\" class=\"advgb-post-tax-term\">Imbruvica<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/articles\/\" class=\"advgb-post-tax-term\">Jaypirca<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/articles\/\" class=\"advgb-post-tax-term\">Small Lymphocytic Lymphoma<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/articles\/\" class=\"advgb-post-tax-term\">Venclexta<\/a>"],"unlinked":["<span class=\"advgb-post-tax-term\">BTK Inhibitor Market<\/span>","<span class=\"advgb-post-tax-term\">BTK Inhibitors<\/span>","<span class=\"advgb-post-tax-term\">Calquence<\/span>","<span class=\"advgb-post-tax-term\">Chronic Lymphocytic Leukemia<\/span>","<span class=\"advgb-post-tax-term\">chronic lymphocytic leukemia treatment<\/span>","<span class=\"advgb-post-tax-term\">chronic lymphocytic leukemia treatment market<\/span>","<span class=\"advgb-post-tax-term\">Eli Lilly<\/span>","<span class=\"advgb-post-tax-term\">Imbruvica<\/span>","<span class=\"advgb-post-tax-term\">Jaypirca<\/span>","<span class=\"advgb-post-tax-term\">Small Lymphocytic Lymphoma<\/span>","<span class=\"advgb-post-tax-term\">Venclexta<\/span>"]}},"comment_count":"0","relative_dates":{"created":"Posted 2 years ago","modified":"Updated 2 years ago"},"absolute_dates":{"created":"Posted on Dec 11, 2023","modified":"Updated on Jan 5, 2024"},"absolute_dates_time":{"created":"Posted on Dec 11, 2023 5:39 pm","modified":"Updated on Jan 5, 2024 10:04 am"},"featured_img_caption":"jaypirca-for-chronic-lymphocytic-leukemia","series_order":"","_links":{"self":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts\/25881","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/users\/14"}],"replies":[{"embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/comments?post=25881"}],"version-history":[{"count":0,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts\/25881\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/media\/25882"}],"wp:attachment":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/media?parent=25881"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/categories?post=25881"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/tags?post=25881"},{"taxonomy":"industry","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/industry?post=25881"},{"taxonomy":"therapeutic_areas","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/therapeutic_areas?post=25881"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}